Arsenoplatin-1 Is a Dual Pharmacophore Anticancer Agent.
Antineoplastic Agents
/ chemistry
Arsenic Trioxide
/ analogs & derivatives
Cell Line, Tumor
Cell Proliferation
/ drug effects
Cisplatin
/ analogs & derivatives
Dose-Response Relationship, Drug
Drug Screening Assays, Antitumor
Humans
Molecular Structure
Organoplatinum Compounds
/ chemistry
Structure-Activity Relationship
Journal
Journal of the American Chemical Society
ISSN: 1520-5126
Titre abrégé: J Am Chem Soc
Pays: United States
ID NLM: 7503056
Informations de publication
Date de publication:
24 04 2019
24 04 2019
Historique:
pubmed:
4
4
2019
medline:
5
8
2020
entrez:
4
4
2019
Statut:
ppublish
Résumé
Arsenoplatins are adducts of two chemically important anticancer drugs, cisplatin and arsenic trioxide, that have a Pt(II) bond to an As(III) hydroxide center. Screens of the NCI-60 human tumor cell lines reveal that arsenoplatin-1 (AP-1), [Pt(μ-NHC(CH
Identifiants
pubmed: 30943017
doi: 10.1021/jacs.8b13681
pmc: PMC6830503
mid: NIHMS1053330
doi:
Substances chimiques
Antineoplastic Agents
0
Organoplatinum Compounds
0
arsenoplatin-1
0
Cisplatin
Q20Q21Q62J
Arsenic Trioxide
S7V92P67HO
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
6453-6457Subventions
Organisme : NCI NIH HHS
ID : U01 CA151461
Pays : United States
Organisme : NCI NIH HHS
ID : U54 CA193419
Pays : United States
Organisme : NCI NIH HHS
ID : U54 CA202995
Pays : United States
Organisme : NCI NIH HHS
ID : U54 CA203000
Pays : United States
Références
Chem Commun (Camb). 2017 Oct 24;53(85):11622-11633
pubmed: 29019481
Angew Chem Int Ed Engl. 2016 Feb 12;55(7):2550-4
pubmed: 26749149
Nature. 2012 Jan 25;481(7382):455-6
pubmed: 22281594
Chemistry. 2017 May 23;23(29):6942-6947
pubmed: 28071831
Leuk Res. 2019 Jan;76:11-14
pubmed: 30472478
Prog Nucleic Acid Res Mol Biol. 2001;67:93-130
pubmed: 11525387
Inorg Chem. 2018 Feb 19;57(4):1717-1726
pubmed: 29400953
Inorg Chem. 2013 Nov 4;52(21):12292-304
pubmed: 24147771
Biomed Pharmacother. 2016 Feb;77:161-6
pubmed: 26796280
Drug Resist Updat. 2015 May;20:1-11
pubmed: 26003720
J Inorg Biochem. 2015 Dec;153:136-142
pubmed: 26239545
Angew Chem Int Ed Engl. 2012 Jul 2;51(27):6742-7
pubmed: 22639083
Chem Rev. 2016 Mar 9;116(5):3436-86
pubmed: 26865551
J Cancer Res Clin Oncol. 2018 Aug;144(8):1561-1568
pubmed: 29789926
Chemistry. 2018 Apr 17;24(22):5790-5803
pubmed: 29314368
Chem Commun (Camb). 2007 Jan 14;(2):156-8
pubmed: 17180231
Mol Cancer Ther. 2010 May;9(5):1451-60
pubmed: 20442306
Eur J Med Chem. 2018 Sep 5;157:1292-1299
pubmed: 30195239
J Biol Chem. 2015 Jul 24;290(30):18361-9
pubmed: 26063799
Angew Chem Int Ed Engl. 2009;48(49):9295-9
pubmed: 19894238
Dalton Trans. 2017 Jul 18;46(28):8929-8932
pubmed: 28654098
Met Ions Life Sci. 2018 Feb 5;18:
pubmed: 29394021
J Biomed Res. 2017 Jan 19;31(3):177-188
pubmed: 28808212
Dalton Trans. 2017 Jan 31;46(5):1467-1480
pubmed: 28074206
Nature. 1965 Feb 13;205:698-9
pubmed: 14287410
Cell Oncol (Dordr). 2014 Apr;37(2):119-29
pubmed: 24599717
J Biol Inorg Chem. 2018 May;23(3):313-329
pubmed: 29396610
Science. 2010 Apr 9;328(5975):240-3
pubmed: 20378816
Cancer Res. 2010 Jan 15;70(2):440-6
pubmed: 20068163
Lung Cancer. 2013 Nov;82(2):222-30
pubmed: 24041618
Angew Chem Int Ed Engl. 2013 Oct 4;52(41):10749-52
pubmed: 24038962
Nat Rev Cancer. 2002 Sep;2(9):705-13
pubmed: 12209159
J Am Chem Soc. 2016 Sep 28;138(38):12494-501
pubmed: 27626288
Chem Soc Rev. 2015 Dec 21;44(24):8773-85
pubmed: 25951946
Chem Sci. 2018 Apr 24;9(18):4299-4307
pubmed: 29780561
Chemistry. 2005 Apr 22;11(9):2849-55
pubmed: 15744707
Chem Commun (Camb). 2018 Mar 13;54(22):2788-2791
pubmed: 29484327
Toxicol Sci. 2012 May;127(1):139-49
pubmed: 22331493
Cancer Sci. 2009 Dec;100(12):2459-64
pubmed: 19769630
Phys Chem Chem Phys. 2017 Jan 4;19(2):1328-1334
pubmed: 27966695